Prednisone
| Evidence Level: L2 | Predicted Indications: 9 |
Table of Contents
Prednisone: Alopecia areata
One-Sentence Summary
Prednisone is a systemic glucocorticoid originally used for autoimmune and inflammatory conditions (such as Crohn disease, adrenocortical insufficiency and acute lymphoblastic leukaemia). The TxGNN model predicts it may be effective for alopecia areata, with no registered clinical trials but 20 publications (including one randomised trial of methotrexate with or without low-dose prednisone) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, prednisone is a systemic glucocorticoid with established efficacy in autoimmune and inflammatory disease, and mechanistically it may be applicable to alopecia areata.
Alopecia areata is a T-cell-mediated autoimmune attack on hair follicles, with collapse of the follicle’s immune privilege. Glucocorticoids suppress T-cell activation and pro-inflammatory cytokine production, which addresses this process directly. This fits prednisone’s existing use across autoimmune disease.
There are caveats. Relapse after withdrawal is common, and the toxicity of long-term systemic steroids limits sustained use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36884234 | 2023 | RCT (design inferred from title) | JAMA Dermatology | Methotrexate alone vs methotrexate plus low-dose prednisone in alopecia areata totalis or universalis; two-step double-blind trial |
| 1444500 | 1992 | Randomised controlled study | Archives of Dermatology | 32 patients given a 6-week prednisone taper, followed by 2% topical minoxidil or vehicle; compared with an open trial of 48 patients |
| 1444509 | 1992 | Review | Archives of Dermatology | Review of therapy, efficacy, safety and mechanism; studies were too heterogeneous to compare drugs meaningfully |
| 791152 | 1976 | Follow-up report | Archives of Dermatology | 18 patients on alternate-day prednisone; initial response but long-term benefit not substantial, with numerous side effects |
| 20804894 | 2010 | Clinical study | Annales de Dermatologie et de Vénéréologie | Efficacy and safety of once-monthly oral prednisone pulse |
| 37467740 | 2023 | Case series | Clinical and Experimental Dermatology | Eight patients with very severe alopecia areata improved on baricitinib plus low-dose corticosteroids |
| 41958306 | 2026 | Retrospective case series | J Eur Acad Dermatol Venereol | Baricitinib plus low-dose prednisone in very severe alopecia areata |
| 4571041 | 1973 | Clinical/immunologic study | Archives of Dermatology | Immunologic studies and prednisone treatment |
| 38650498 | 2024 | Real-world observational study | Ital J Dermatol Venereol | Comorbidities, treatment patterns and economic burden in hospitalised patients in Italy |
| 4684625 | 1973 | Case report | Canadian Medical Association Journal | Two alopecia totalis cases; shorter systemic corticosteroid courses may suffice |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00232378 | TEVA-PREDNISONE | Not specified | Not specified |
| 00271373 | WINPRED | Not specified | Not specified |
| 00312770 | APO PREDNISONE TAB 5MG | Tablet (5 mg) | Not specified |
| 00021695 | TEVA-PREDNISONE | Not specified | Not specified |
| 00550957 | APO PREDNISONE TAB 50MG | Tablet (50 mg) | Not specified |
Safety Considerations
- Knowledge-graph contraindication signals (not label text): hypertension, congestive heart failure, epilepsy, hyperglycaemia, measles, herpes simplex virus keratitis, urea-cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia), and a range of pituitary hormone deficiency and hypogonadotropic hypogonadism conditions.
- Drug interactions: 100 interactions were identified. Of those shown, one is Major (adalimumab). Most others are Moderate, including zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alefacept, alemtuzumab, aliskiren and tetanus toxoid. Formoterol and salbutamol are Minor.
- Literature signals: the 1976 follow-up report noted acne, obesity, lenticular opacities and mild hypertension with prednisone. Relapse after withdrawal is common.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Alopecia areata is the strongest of the ten predictions. It has a plausible immune mechanism and a randomised trial of prednisone-containing therapy, plus older clinical studies. However, no registered trials were found, the evidence is mostly small or older studies, benefit is often not durable, and long-term systemic steroid toxicity is a real concern.
To proceed, the following is needed:
- Canadian package insert warnings, contraindications and approved indications (currently unavailable)
- Detailed mechanism of action data
- Verification of the design of the 2023 randomised trial against its registration
- A plan for dose limitation, relapse management and steroid toxicity monitoring (blood pressure, glucose, bone health, infection risk)
- A review of interactions, especially with adalimumab and other immunosuppressants
Other Predicted Indications (Brief)
| Rank | Predicted Indication | Evidence Level | Recommendation | Comment |
|---|---|---|---|---|
| 2 | Alopecia mucinosa | L5 | Hold | Case reports only; the lymphoma-associated form needs different management |
| 3 | Telogen effluvium | L5 | Hold | No evidence; usually self-limiting and non-autoimmune |
| 5 | Alopecia antibody deficiency | L5 | Hold | Retrieved papers do not address this entity |
| 6 | Hereditary hypotrichosis with recurrent skin vesicles | L5 | Hold | Genetic disorder; likely a TxGNN model (deep learning) artifact |
| 7 | Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | L5 | Hold | Rare genetic syndrome; no plausible mechanism |
| 8 | Atrichia with papular lesions | L5 | Hold | Non-immune genetic disorder |
| 10 | Prolapse of lacrimal gland | L5 | Hold | Structural condition; likely a TxGNN model (deep learning) artifact |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.